ABVC BioPharma Boosts Fixed Assets to $12.8 Million via $8 Million Puli Land Acquisition
ABVC’s net property and equipment rose to $12.8 million in 2025 from $511,088 in 2024 due to strategic Asian land acquisitions. The 69,230.9 sqm Puli site is appraised at $8 million and will support medicinal plant cultivation and biotech processing with annual output of $60,000–$360,000.
1. 2025 Annual Report and Asset Increase
ABVC filed its 2025 Annual Report on Form 10-K, revealing net property and equipment climbed to $12,835,409 from $511,088 in 2024. This surge reflects strategic land acquisitions across Asia designed to bolster long-term infrastructure and support future healthcare-related development.
2. Puli Township Acquisition Details
A 69,230.9 sqm property in Puli Township, Nantou is independently appraised at approximately $8 million and title transfer is underway. ABVC plans phased development into a medicinal plant cultivation base, localized pharmaceutical supply platform and biotech processing facility targeting $60,000–$360,000 in annual output.
3. Transition to Hybrid Asset Model
ABVC is shifting from a purely IP-driven biotech structure to a hybrid model combining licensing revenue, equity stakes in development subsidiaries and tangible real assets. This strategy aims to separate development risk, preserve upside participation and reduce capital intensity through strategic land holdings.